Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lena Klopp‐Schulze
Observed names:
Klopp-Schulze Lena,
Klopp-Schulze, Lena,
L. Klopp-Schulze,
Lena Klopp-Schulze
Institutions:
Merck Healthcare Germany GmbH (Germany),
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
Merck KGaA, Darmstadt (Germany),
University of Potsdam,
Karolinska Institutet,
Merck Healthcare Germany GmbH (Germany),
Merck Healthcare KGaA, Darmstadt (Germany),
Freie Universität Berlin
show all 6
ORCID:
0000-0002-2942-3416
Observed ORCID:
0000-0002-2942-3416
OpenAlex ID:
A5052156273
Perspectives on Model‐Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations
2020
·
Franziska Kluwe
, Robin Michelet
, et al.
·
Clinical Pharmacology & Therapeutics
·
88
PDF
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
2021
·
Andreas Port
, Jamie V. Shaw
, et al.
·
Pharmacology Research & Perspectives
·
57
PDF
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
2020
·
Lena Klopp-Schulze
, Anna Mueller-Schoell
, et al.
·
Frontiers in Pharmacology
·
34
PDF
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
2020
·
Anna Mueller‐Schoell
, Lena Klopp‐Schulze
, et al.
·
Clinical Pharmacology & Therapeutics
·
28
PDF
Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial
2024
·
Lena Klopp‐Schulze
, Sathej Gopalakrishnan
, et al.
·
Clinical Pharmacology & Therapeutics
·
25
Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients
2017
·
Lena Klopp-Schulze
, Markus Joerger
, et al.
·
Clinical Pharmacokinetics
·
22
Applying Modeling and Simulations for Rational Dose Selection of Novel Toll‐Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need
2022
·
Lena Klopp‐Schulze
, Jamie V. Shaw
, et al.
·
Clinical Pharmacology & Therapeutics
·
21
PDF
Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
2020
·
Yulia Vugmeyster
, Justin Wilkins
, et al.
·
Clinical Pharmacology & Therapeutics
·
20
PDF
Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study
2025
·
Torsten Witte
, Ruth Fernandez-Ruiz
, et al.
·
Lupus Science & Medicine
·
19
PDF
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
2026
·
Eric F Morand
, Maria Dall'Era
, et al.
·
The Lancet
·
17
PDF
Cerulein-induced pancreatic fibrosis is modulated by Smad7, the major negative regulator of transforming growth factor-β signaling
2016
·
Xuan Li
, Salvatore Nania
, et al.
·
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
·
17
PDF
Enpatoran in COVID ‐19 pneumonia: Safety and efficacy results from a phase II randomized trial
2023
·
John E. McKinnon
, Joel Santiaguel
, et al.
·
Clinical and Translational Science
·
12
PDF
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus
2023
·
Kosalaram Goteti
, Ramon Garcia
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
11
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial
2026
·
Eric F Morand
, Victoria P Werth
, et al.
·
The Lancet Rheumatology
·
9
Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler
2024
·
Hong Lu
, Lena Klopp‐Schulze
, et al.
·
Clinical and Translational Science
·
6
PDF
Adherence to tamoxifen in breast cancer patients: What role does the pharmacist play in German primary care?
2018
·
Madlene Schulz
, Lena Klopp-Schulze
, et al.
·
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
·
6
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
2021
·
Anna Mueller-Schoell
, Lena Klopp-Schulze
, et al.
·
Pharmaceuticals
·
5
PDF
Lb0004 Randomised, Placebo-controlled Phase Ii Study of Oral Enpatoran, a First-in-class Toll-like Receptor 7/8 Inhibitor, in Systemic Lupus Erythematosus
2025
·
E. Morand
, M. Dall'Era
, et al.
·
Annals of the Rheumatic Diseases
·
4
Pos1268 Phase Ii Trial of Enpatoran in Patients Hospitalized With Covid-19 Pneumonia
2022
·
J.E. Mckinnon
, J. Santiaguel
, et al.
·
Annals of the Rheumatic Diseases
·
2
PDF
518. Model-informed Dose Selection of Dual Toll-like Receptor 7/8 Inhibitor Enpatoran (M5049) for the Treatment of COVID-19 Pneumonia
2021
·
Lena Klopp-Schulze
, Jamie Shaw
, et al.
·
Open Forum Infectious Diseases
·
2
PDF
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
2021
·
Anna Mueller-Schoell
, Robin Michelet
, et al.
·
Cancers
·
2
PDF
Pos0755 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Orally Administered Dose of Enpatoran in a Phase I Study of Healthy Japanese and Caucasian Participants
2022
·
S. Gopalakrishnan
, A. Krebs-Brown
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
2016
·
Lena Klopp-Schulze
, Markus Joerger
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
1
Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs
2026
·
Johannes Tillil
, Sathej Gopalakrishnan
, et al.
·
Clinical Pharmacology & Therapeutics
PDF
Mechanism–endpoint matching in lupus: WILLOW Cohort B – Authors' reply
2026
·
Eric F Morand
, Ruth Fernandez-Ruiz
, et al.
·
The Lancet
Show more works
View as search
Works count:
34
Citation count:
409
H-index:
12
I10-index:
13
Year
Topic
Type